Auration Biotech is focused on developing innovative therapeutics specifically aimed at treating diseases related to the ear, nose, and throat. The company has established a pipeline that includes AU-935, which utilizes heparin-binding epidermal growth factor (HB-EGF) for the non-surgical repair of tympanic membranes, and AU-934, an alternative to traditional tympanotomy tubes. These products are designed to address chronic tympanic membrane perforations and enhance healing processes, showcasing Auration Biotech's commitment to advancing treatment options in otolaryngology.

The technologies employed by Auration Biotech leverage the regenerative properties of HB-EGF, which has demonstrated efficacy in promoting the healing of tympanic membrane injuries in animal models. Research indicates that this growth factor can facilitate wound healing more effectively than other agents, such as fibroblast growth factor 2 and epidermal growth factor. The company is also exploring additional undisclosed products in its research pipeline, indicating a robust commitment to innovation in therapeutic solutions for ear, nose, and throat conditions.

United States

About Auration Biotech, Inc Vision: To develop novel therapeutics for treatment of diseases of the ear, nose and throat. History: Founded in 2014 Founders:
Benjamin F. McGraw, III, PharmD (Executive Chairman)
Sanjay Chanda, PhD (Development Consultant)
Peter Santa Maria, MBBS, PhD, FRACS (Chairman, SAB) Programs:
AU-935 (HB-EGF), non-surgical repair of tympanic

Auration Biotech

Company Details